It is usually said kindly, and it is almost always said last.
The examination is over, the dressing is back on, and as you reach for your coat: the best thing you could do for this is lose some weight. No mechanism. No prescription. No follow-up. You leave with homework instead of treatment, and you carry home with it the quiet implication that this disease — the one that has cost you jobs, sleep, clothing and intimacy — is at some level your own doing.
Here is what makes it so hard to argue with, and so damaging: it is not entirely wrong.
Start with what is true
The association is real. It is documented, it is repeated, and it is not going away. Higher body weight tracks with HS prevalence and with severity. Mechanical factors are real too — friction, skin-on-skin occlusion, trapped heat and moisture genuinely aggravate lesions that already exist. Anyone who has had a groin lesion in July does not need a citation for this.
We are not going to insult you by denying something you can feel.
But aggravating a lesion that exists and causing the disease that produced it are entirely different claims. The advice slides quietly from the first to the second, and nobody notices the join.
The causal arrow is pointing the wrong way
What drives HS is metabolic and immune, not mechanical.
Insulin resistance produces hyperinsulinaemia. High circulating insulin suppresses sex hormone-binding globulin, raising the fraction of free, biologically active androgen. It also raises IGF-1 activity. Both act on the pilosebaceous unit: the follicular lining thickens and sheds abnormally, the duct plugs, apocrine secretion accumulates behind the plug, pressure rises, and the follicle ruptures into the dermis. The abscess, the tract, the scar — all of it is the immune system responding to that rupture.
Now look at what the same hyperinsulinaemia does elsewhere. It promotes fat storage. It suppresses fat mobilisation. It disturbs satiety signalling. It is, in physiological terms, the definition of a body that stores easily and releases reluctantly.
One driver. Two outputs. The follicles plug and the weight climbs — not because one caused the other, but because both sit downstream of the same signalling failure.
For a great many HS patients, weight is not the cause of the disease. It is a co-symptom of the same driver.
Which is precisely how a person can lose weight — properly, with real and sustained effort — and still flare. They corrected an output. Nobody touched the driver.
The patients the advice cannot explain
Lean people get HS.
Slim, athletic, low-BMI patients present with EPOH-DSS Stage 3 disease — established sinus tracts, active tunnelling — and have nothing to lose. If adiposity were the cause, these patients should not exist. They do exist, in numbers no honest clinician can wave away. Many of them are insulin-resistant at a normal BMI, because insulin resistance is a signalling state, not a size. And the association between HS and metabolic syndrome is reported independently of body mass index.
An explanation that cannot account for a large share of the patients it claims to explain is not an explanation. It is a habit.
What the advice is actually asking of you
Set the fairness question aside for a moment and look at the engineering of it. "Lose weight" asks you to solve an output using machinery the disease has already broken.
- Movement. Chronic pain in the groin, the axilla or under the breast makes exercise punishing, and during a flare impossible. You are being asked to work the exact anatomy that is currently wounded.
- Endocrinology. Sustained inflammatory signalling and a dysregulated cortisol rhythm push physiology toward storage and disturb appetite regulation. You are not fighting your habits. You are fighting your own signalling.
- Sleep. Pain wakes you. Dressings wake you. Short, fragmented sleep worsens insulin resistance and flattens cortisol rhythm — deepening the very driver you are being told to out-discipline.
- Isolation. The disease is painful, unpredictable and stigmatised. Food is one of very few comforts that does not require you to be seen.
So the instruction hands you a target, removes the tools, and then — when the target is missed — returns the blame to your character. It is not merely incomplete advice. It is advice built to fail in a way that looks like your fault.
That is why patients find it demoralising. Not because it is harsh, but because it relocates responsibility for an inflammatory disease onto their personality, and then ends the appointment.
What was actually missed
The driver.
Metabolic function is one of five internal driver systems. The other four — gut health, hormonal balance, immune regulation, stress and cortisol — were all sitting there, unexamined, in an appointment that closed with a remark about your weight. In EPOH, treatment is built from a patient's driver profile, not from the condition name, which is why two people with identical-looking disease receive different formulations.
What correcting the driver involves
Phase L — Lowering the Load (4–8 weeks). Oral formulations reducing accumulated inflammatory load (Ama), with digestive support and immune-calming compounds, taken at home. Diet is complementary in this phase — a supporting input, never the phase itself, and never a hurdle you must clear before treatment is permitted to begin. Nobody earns their treatment by losing weight first.
Phase I — Internal Healing (8–16 weeks). The primary correction phase: gut lining integrity, microbiome repair, immune recalibration, and hormonal and metabolic patterns — including insulin signalling, SHBG and free androgen load. This is where the mechanism at the top of this article is addressed directly.
Phase F — Functional Detox comes third, never first — oral formulations supporting lymphatic and tissue-level clearance from within, not a procedure. Applied before L and I are stable, it mobilises internal load faster than the body can clear it, and the patient gets worse. Phase E adds topical formulations for lesion resolution and sinus-tract healing, working because internal conditions have already shifted. Phase S sustains the result.
In Ayurvedic terms the sequence begins with weakened Agni — digestive and metabolic fire — allowing Ama to accumulate, with Kapha-driven sluggishness and Pitta-driven inflammatory heat obstructing the Svedavaha Srotas. The same cascade in an older vocabulary. It does not begin at the waistline either.
Weight usually moves — afterwards
Here is what tends to happen when the driver is corrected rather than scolded.
When insulin signalling improves, storage stops being the body's default setting. When inflammatory load falls, the appetite dysregulation that travels with it falls too. When lesions quieten, sleep returns; when sleep returns, cortisol rhythm and glucose handling improve together. When pain reduces, movement becomes possible again — not as a moral achievement, but because it has stopped hurting.
So yes, weight often does come down. It comes down as a consequence of correction, not as a precondition for it.
That is the correct order. Reversing it is the most common reason HS patients spend years working extremely hard on the wrong variable and then conclude that they failed.
None of this means food is irrelevant. It means food is an input to a driver — and the driver is what is being treated.
Honest expectations
Recovery Stage 1 (Internal Shift, weeks 1–4) is mostly invisible; four to eight weeks of internal work before visible surface change is normal. Between weeks 3 and 6, expect the Partial Improvement Plateau — genuine improvement, then flares continuing anyway. This is not failure. It signals that Phase L has done its work and Phase I should begin. Patients who quit, quit here. Recovery Stage 2 (Reduced Frequency) runs months 2–4, Recovery Stage 3 (Reduced Severity) months 4–8, Recovery Stage 4 (Stable Remission) from month 8. These are treatment-response stages, not EPOH-DSS severity stages — a patient can be EPOH-DSS Stage 3 (Sinus) and Recovery Stage 2 simultaneously.
Not every patient responds equally. Disease duration, degree of organ involvement, and remaining biological repair capacity all influence outcomes. Patients with very advanced structural changes (severe fibrotic HS) may not achieve full remission. A personalised evaluation is the only way to assess your specific response potential.
You begin while continuing your current medication; as correction takes effect, any reduction is reviewed with your prescribing physician and tapered gradually.
You were given a chore, not a plan
If the whole of your treatment plan was a comment about your weight, you were not treated. You were dismissed politely.
A personalised evaluation maps your actual driver profile, and formulations are compounded to it and dispatched by courier. Consultation and monitoring are by video or WhatsApp. There is no clinic visit at any stage — and no weight target you must hit before you are allowed to start.
